The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Acral melanoma tumors may require more aggressive surgical treatment

Forums General Melanoma Community Acral melanoma tumors may require more aggressive surgical treatment

  • This topic is empty.
  • Post
    JC
    Participant

      Acral melanoma tumors may require more aggressive surgical treatment

       

      Gunmaste PV. J Clin Oncol. 32:5s, 2014. (suppl; abstr 9052).

       

      June 11, 2014

       

       

      Acral melanoma was found to have higher recurrence and lower survival rates than other types of melanoma and may require more aggressive surgical intervention, according to researchers.

       

          

      The researchers selected patients from a prospectively enrolled cohort of primary melanoma patients at NYU Langone Medical Center; 61 patients with acral melanoma and 183 patients with non-acral melanoma were included. Median follow-up was 33 months in the acral melanoma cohort and 58 months in the non-acral melanoma cohort.

       

      Compared with non-acral melanoma, the acral histologic subtype was found to be an independent negative predictor of recurrence-free survival (P < .001) and melanoma-specific survival (P = .001), according to the researchers.

       

      Recurrence rates were significantly higher in patients with acral melanoma (49%) compared with patients who had non-acral melanoma (30%; P = .007).

       

      The researchers also found that in tumors with a thickness of less than 2 mm, there was a significantly higher recurrence rate of acral melanoma at 28% compared with non-acral melanoma at 10% (P = .048). Additionally, the rate of loco-regional recurrence was nearly double among patients with acral melanoma (39%) compared with patients who had non-acral melanoma (19%; P = .001).

       

      Disclosure: The study was supported by the Perlmutter NYU Cancer Institute NCI Cancer Center Support Grant (5 P30 CA 016087-2), and the Marc Jacobs Campaign to support melanoma research. Stein received support by the Irwin I. Lubowe Fellowship in Dermatology.

    • You must be logged in to reply to this topic.
    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.